Search Results for "vitamin D"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vitamin D. Results 31 to 40 of 118 total matches.
Comparison Table: Some Drugs for Plaque Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
Dosage3 Adverse Effects and Drug Interactions Pregnancy and Lactation4 Class Comments
Topical Vitamin D ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6 doi:10.58347/tml.2024.1712b | Show Introduction Hide Introduction
Guselkumab (Tremfya) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017 (Issue 1533)
treated with
topical corticosteroids. Topical vitamin D analogs
and the retinoid tazarotene (Tazorac ...
The FDA has approved the interleukin (IL)-23 blocker
guselkumab (Tremfya – Janssen) for treatment of
moderate to severe plaque psoriasis in adults who
are candidates for systemic therapy or phototherapy.
Guselkumab is the first selective IL-23 blocker to
become available in the US.
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
-FU in combination with the vitamin
D derivative calcipotriene (off-label) twice daily for 4
days ...
Tirbanibulin, a microtubule inhibitor, has been
approved by the FDA as a 1% ointment (Klisyri –
Almirall) for topical treatment of actinic keratosis of
the face or scalp.
Intravenous Ibandronate (Boniva)
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
, patients
being treated with IV ibandronate should take supplemental calcium and vitamin D. The drug ...
Ibandronate (Boniva - Roche) is the first bisphosphonate approved by the FDA for intravenous (IV) treatment of osteoporosis in postmenopausal women. It is given as a bolus injection once every 3 months. Ibandronate is also available as an oral once-a-month 150-mg tablet and as a daily 2.5-mg tablet.
Secukinumab (Cosentyx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
associated
with multiple comorbidities.1 Topical preparations,
including corticosteroids and vitamin D ...
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who are
candidates for systemic therapy or phototherapy.
It is the first IL-17 inhibitor to be approved for any
indication in the US.
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
condition. Mild to moderate psoriasis is generally
treated with topical corticosteroids. Topical vitamin
D ...
The FDA has approved brodalumab (Siliq – Valeant),
an injectable human interleukin (IL)-17A receptor
antagonist, for treatment of adults with moderate to
severe plaque psoriasis who have failed to respond
to other systemic therapies. Brodalumab is the third
IL-17A antagonist to be approved in the US for this
indication; secukinumab (Cosentyx) and ixekizumab
(Taltz) were approved earlier.
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
is generally treated with topical corticosteroids.
Topical vitamin D analogs and the retinoid tazarotene ...
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy
or phototherapy. Ixekizumab is the second IL-17A
antagonist to be approved for this indication in the US;
secukinumab (Cosentyx – Novartis) was the first.
In Brief: Airborne
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005 (Issue 1199)
and treatment of colds. It contains 7 herbal extracts, 3
vitamins, 2 amino acids, selenium, zinc and many ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
A Once-Yearly IV Bisphosphonate for Osteoporosis
The Medical Letter on Drugs and Therapeutics • Nov 05, 2007 (Issue 1273)
should also take daily oral calcium and vitamin D
supplements. The drug is not recommended for
patients ...
Zoledronic acid (Reclast - Novartis) is the first bisphosphonate approved by the FDA for once-yearly intravenous (IV) treatment of osteoporosis in postmenopausal women. Reclast is also approved for treatment of Paget's disease. Another IV formulation of zoledronic acid (Zometa) is approved for treatment of hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors.
Tapinarof Cream (Vtama) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
. The topical retinoid
tazarotene or a topical vitamin D analog such as
calcipotriene or calcitriol have also ...
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist to be
approved by the FDA.